Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Epitalon (AEDG) (AEDG) is a anti-aging peptide, at the preclinical stage in the published literature. Alternative name for Epithalon - the Ala-Glu-Asp-Gly tetrapeptide with telomerase-activating properties.
Alternative name for Epithalon - the Ala-Glu-Asp-Gly tetrapeptide with telomerase-activating properties.
| Research Status | Preclinical |
|---|---|
| Half-Life | Unknown |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 5-10 mg daily (20-day cycles) |
Same as Epithalon - activates telomerase enzyme to maintain telomere length.
Alternative name for Epithalon - the Ala-Glu-Asp-Gly tetrapeptide with telomerase-activating properties.
Same as Epithalon - activates telomerase enzyme to maintain telomere length.
Epitalon (AEDG) is at the following stage in the published literature: Preclinical. All information is for research and educational purposes only.
Reported half-life: Unknown.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.